Patents by Inventor Renier J. Brentjens

Renier J. Brentjens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-36 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF
    Publication number: 20240108705
    Abstract: The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to an immunoresponsive cell comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), and expressing increased level of IL-36. In certain embodiments, the engineered immunoresponsive cells are antigen-directed and have enhanced immune-activating properties.
    Type: Application
    Filed: August 10, 2023
    Publication date: April 4, 2024
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Anthony Daniyan, Renier J. Brentjens
  • ANTIBODIES TARGETING G-PROTEIN COUPLED RECEPTOR AND METHODS OF USE
    Publication number: 20240076370
    Abstract: The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.
    Type: Application
    Filed: December 22, 2022
    Publication date: March 7, 2024
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
  • ANTIGEN RECOGNIZING RECEPTORS TARGETING GD3 GANGLIOSIDE AND USES THEREOF
    Publication number: 20240042031
    Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target GD3 and cells comprising such GD3-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the GD3-targeted antigen-recognizing receptors for treatment.
    Type: Application
    Filed: September 28, 2023
    Publication date: February 8, 2024
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher S. Hackett, Renier J. Brentjens, Jedd D. Wolchok, Paul B. Chapman, Sarwish Rafiq, Terence Purdon
  • Nucleic acid molecules encoding chimeric antigen receptors targeting G-protein coupled receptor
    Patent number: 11866478
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor (e.g., a G-protein coupled receptor family C group 5 member D (GPRC5D)), and immunoresponsive cells comprising such CARs. The presently disclosed CARs targeting a G-protein coupled receptor (e.g., GPRC5D) have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: January 9, 2024
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L Smith, Cheng Liu
  • Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof
    Patent number: 11820806
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor (e.g., a G-protein coupled receptor family C group 5 member D (GPRC5D)), and immunoresponsive cells comprising such CARs. The presently disclosed CARs targeting a G-protein coupled receptor (e.g., GPRC5D) have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: November 21, 2023
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
  • IL-36 secreting immunoresponsive cells and uses thereof
    Patent number: 11766474
    Abstract: The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to an immunoresponsive cell comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), and expressing increased level of IL-36. In certain embodiments, the engineered immunoresponsive cells are antigen-directed and have enhanced immune-activating properties.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: September 26, 2023
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Anthony Daniyan, Renier J. Brentjens
  • Antibodies targeting B-cell maturation antigen and methods of use
    Patent number: 11725059
    Abstract: The presently disclosed subject matter provides antibodies that bind to B-cell maturation antigen (BCMA) and methods of using the same.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: August 15, 2023
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
  • IL-33 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF
    Publication number: 20230242879
    Abstract: The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to an immunoresponsive cell comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), and expressing increased level of IL-33. In certain embodiments, the engineered immunoresponsive cells are antigen-directed and have enhanced immune-activating properties.
    Type: Application
    Filed: March 23, 2023
    Publication date: August 3, 2023
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Anthony Daniyan, Renier J. Brentjens
  • CHIMERIC ANTIGEN RECEPTORS WITH CD28 MUTATIONS AND USE THEREOF
    Publication number: 20230051064
    Abstract: The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) comprising a mutated CD28 intracellular motif, and cells comprising such CARs. The presently disclosed subject matter further relates to the use of said cells for treating diseases, e.g., for treating cancers.
    Type: Application
    Filed: August 5, 2022
    Publication date: February 16, 2023
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Anthony Daniyan, Renier J. Brentjens
  • Nucleic acid molecules encoding anti-GPRC5D antibodies
    Patent number: 11566071
    Abstract: The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: January 31, 2023
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
  • CHIMERIC ANTIGEN RECEPTORS TARGETING FC RECEPTOR-LIKE 5 AND USES THEREOF
    Publication number: 20230020729
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating a neoplasia (e.g., multiple myeloma). It relates to chimeric antigen receptors (CARs) that specifically target Fc Receptor-like 5 (FcRL5), e.g., domain 9 of FcRL5, and immunoresponsive cells comprising such CARs. The presently disclosed FcRL5-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: May 27, 2021
    Publication date: January 19, 2023
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
  • ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF USE
    Publication number: 20220315660
    Abstract: The presently disclosed subject matter provides antibodies that bind to B-cell maturation antigen (BCMA) and methods of using the same.
    Type: Application
    Filed: February 11, 2021
    Publication date: October 6, 2022
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Chen Liu
  • ANTIGEN RECOGNIZING RECEPTORS TARGETING CD371 AND USES THEREOF
    Publication number: 20220213211
    Abstract: The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target CD371 and cells comprising such CD371-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the CD371-targeted antigen-recognizing receptors for treatment.
    Type: Application
    Filed: March 11, 2022
    Publication date: July 7, 2022
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Anthony Daniyan, Renier J. Brentjens, Ivo C. Lorenz, Mary Ann Pohl
  • ANTI-CD371 ANTIBODIES AND USES THEREOF
    Publication number: 20220195064
    Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to CD371 and methods of using such antibodies or antigen-binding fragments thereof same.
    Type: Application
    Filed: March 11, 2022
    Publication date: June 23, 2022
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Anthony Daniyan, Renier J. Brentjens, Ivo C. Lorenz, Mary Ann Pohl
  • COMBINATION THERAPIES
    Publication number: 20220054550
    Abstract: The presently disclosed subject matter provides combination therapies for treating diseases or disorders, e.g., cancers. In particular, the present disclosure provides methods of treatment comprising administering genetically engineered cells and radiation.
    Type: Application
    Filed: October 28, 2021
    Publication date: February 24, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Eric L. Smith, Renier J. Brentjens
  • ANTIBODIES TARGETING FC RECEPTOR-LIKE 5 AND METHODS OF USE
    Publication number: 20210388081
    Abstract: The presently disclosed subject matter provides fully human antibodies or antigen-binding fragments thereof that bind to FcRL5 and methods of using the same.
    Type: Application
    Filed: January 7, 2021
    Publication date: December 16, 2021
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
  • COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
    Publication number: 20210369781
    Abstract: The present invention provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells bearing antigen receptors, which can be chimeric antigen receptors (CARs), which express introduced ligands for immunomodulatory molecules. In particular embodiments, engineered immunoresponsive cells are antigen-directed and resist immunosuppression and/or have enhances immune-activating properties.
    Type: Application
    Filed: August 12, 2021
    Publication date: December 2, 2021
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Renier J. Brentjens, Hollie J. Jackson
  • METHODS OF USING CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND USES THEREOF
    Publication number: 20210346432
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target B cell maturation antigen (BCMA), and immunoresponsive cells comprising such CARs. The presently disclosed BCMA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: April 12, 2021
    Publication date: November 11, 2021
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
  • PD-1 immune modulating agents
    Patent number: 11136392
    Abstract: The present application provides anti-PD-1 antigen-binding proteins or a fragment thereof, as well as nucleic acids encoding anti-PD-1 antigen-binding proteins or CAR T cells expressing such antigen-binding protein or fragment. Also provided are methods of regulating T cells or treating patients using such constructs or cells.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: October 5, 2021
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Hollie Jaine Jackson, Cheng Liu
  • PD-1 immune modulating agents
    Patent number: 11104733
    Abstract: The present application provides anti-PD-1 antigen-binding proteins or a fragment thereof, as well as nucleic acids encoding anti-PD-1 antigen-binding proteins or CAR T cells expressing such antigen-binding protein or fragment. Also provided are methods of regulating T cells or treating patients using such constructs or cells.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 31, 2021
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Hollie Jaine Jackson, Cheng Liu